Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 4/20 | 0.40 |
| ▸ | AGXT | P21549 | 2/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.38 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5621169 | 0.82 | MAOB (0.44) | MAOBIDO1AGXTMAPK14 | |
| SCHEMBL2556251 | 0.77 | LIPE (0.55) | MAOBIDO1AGXTMAPK14PTGER1 | |
| SCHEMBL5109133 | 0.73 | IDO1 (0.46) | MAOBIDO1AGXTMAPK14PTGER1 | |
| SCHEMBL5109200 | 0.72 | PTGER1 (0.44) | IDO1PTGER1MRGPRX4 | |
| SCHEMBL1409369 | 0.70 | ENPP2 (0.42) | MAOBMEN1KMT2A | |
| SCHEMBL29955963 | 0.70 | ENPP2 (0.42) | MAOBMEN1KMT2A | |
| SCHEMBL2557415 | 0.69 | MAOB (0.50) | MAOBIDO1AGXTMAPK14GSK3B | |
| SCHEMBL2555813 | 0.68 | ALDH1A1 (0.48) | MEN1KMT2A | |
| SCHEMBL5109243 | 0.68 | CCR5 (0.58) | MAOBMAPK14PTGER1 | |
| SCHEMBL5620813 | 0.68 | PTGER1 (0.52) | MAOBMAPK14MEN1KMT2APTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | GLAXOSMITHKLINE | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275053-A1 | Selective modulators of prostaglandin E2 at EP1 receptors; analgesics, antiinflammatory agents; neurodegenerative diseases, bone or renal disorders; 3-{1-[2-(benzyloxy)-phenyl]-5-methyl-1H-pyrrol-2-yl}-benzoic acid | PTGER1, PTGER2, PTGDR | MAOB 571/4885IDO1 1081/4885AGXT 3092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.